BioAge Labs Plunges Over 60% After Novo’s ZEUS Trial Failure — Citi Says the Sell-Off Is Overdone
BioAge Labs shares fell over 60% after Novo Nordisk’s ZEUS trial failed to cut MACE. Citi says the sell-off is excessive despite negative ASCVD impact.
/ 1648 items
#XY↓
Private-Equity Firm KKR Near Agreement to Take Medical-Device Maker Integer Holdings Private
KKR nears deal to take Integer Holdings private at $127/share. Announcement possible next week; values the medical-device CDMO at ~$4.3B.
Neurocrine Stock Weak Despite Strong Q2 Beat and Raise; Analysts Call Dip “Overdone”
Neurocrine reported $959M Q2 revenue (+39%) and raised Ingrezza guidance. Stock fell on short-term concerns, but analysts call the dip overdone and raise targets.
B. Riley Initiates Coverage on 4D Molecular with $37 Target — 267% Upside Potential
4D Molecular’s gene therapy could reduce eye injections for AMD patients. B. Riley sees major upside if Phase 3 results succeed. 4D-150 gene therapy fully funded to H2 2028.
Novo Nordisk’s Anti-Inflammatory Drug Fails Key Heart Trial
Novo Nordisk’s ziltivekimab failed to reduce major cardiovascular events in the late-stage ZEUS trial of high-risk patients.
Moderna Beats Revenue Estimates on Strong COVID Sales, but Shares Drop on Norovirus Setback
Moderna reported $145M Q2 revenue, beating $103M estimates on strong COVID vaccine sales. Shares fell after norovirus vaccine missed key trial goal.